ProQR Therapeutics N.V. announced a collaboration with the Rett Syndrome Research Trust (RSRT) that will focus on the design and development of editing oligonucleotides (EONs) using ProQR's Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (MECP2) and correcting mutations of interest.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | -1.02% | -2.51% | -2.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.02% | 158M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PRQR Stock
- News ProQR Therapeutics N.V.
- ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration